Literature DB >> 17224197

Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models.

Tiziana Rancati1, Berit Wennberg, Pehr Lind, Gunilla Svane, Giovanna Gagliardi.   

Abstract

OBJECTIVE: To fit four different NTCP (Normal Tissue Complication Probability) models to prospectively collected data on short-term pulmonary complications following breast cancer radiotherapy (RT). MATERIALS/
METHODS: Four hundred and seventy-five breast cancer patients, referred to the Radiotherapy Department at Stockholm Söder Hospital (1994-1998) for adjuvant post-operative RT were prospectively followed for pulmonary complications 1, 4 and 7 months after the completion of RT. Eighty-seven patients with complete dose-volume histogram (DVH) of the ipsilateral lung were selected for the present analysis. Mean dose to the ipsilateral lateral lung ranged from 2.5 to 18Gy (median 12Gy). Three different endpoints were considered: (1) clinical pneumonitis scored according to CTC-NCIC criteria: asymptomatic (grade 0) vs grade 1 and grade 2; (2) radiological changes assessed with diagnostic chest X-ray: no/slight radiological changes vs moderate/severe; (3) radiological changes assessed with CT: no/slight vs moderate/severe. Four NTCP models were used: the Lyman model with DVH reduced to the equivalent uniform dose (LEUD), the Logit model with DVH reduced to EUD, the Mean Lung Dose (MLD) model and the Relative Seriality (RS) model. The data fitting procedure was done using the maximum likelihood analysis. The analysis was done on the entire population (n=87) and on a subgroup of patients treated with loco-regional RT (n=44).
RESULTS: 24/87 patients (28%) developed clinical pneumonitis; 28/81 patients (35%) had radiological side effects on chest X-rays and 11/75 patients (15%) showed radiological density changes on Computed Tomography (CT). The analysis showed that the risk of clinical pneumonitis was a smooth function of EUD (calculated from DVH using n=0.86+/-0.10, best fit result). With LEUD, the relationship between EUD and NTCP could be described with a D(50) of 16.4Gy+/-1.1Gy and a steepness parameter m of 0.36+/-0.7. The results found in the overall population were substantially confirmed in the subgroup of patients treated with loco-regional RT.
CONCLUSIONS: A large group of prospective patient data (87 pts), including grade 1 pneumonitis, were analysed. The four NTCP models fit quite accurately the considered endpoints. EUD or the mean lung dose are robust and simple parameters correlated with the risk of pneumonitis. For all endpoints the D(50) values ranged in an interval between 10 and 20Gy.

Entities:  

Mesh:

Year:  2007        PMID: 17224197     DOI: 10.1016/j.radonc.2006.12.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

Review 1.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  A graphic user interface toolkit for specification, report and comparison of dose-response relations and treatment plans using the biologically effective uniform dose.

Authors:  Fan-Chi Su; Panayiotis Mavroidis; Chengyu Shi; Brigida Costa Ferreira; Niko Papanikolaou
Journal:  Comput Methods Programs Biomed       Date:  2010-03-24       Impact factor: 5.428

3.  Assessing four-dimensional radiotherapy planning and respiratory motion-induced dose difference based on biologically effective uniform dose.

Authors:  F-C Su; C Shi; P Mavroidis; V Goytia; R Crownover; P Rassiah-Szegedi; N Papanikolaou
Journal:  Technol Cancer Res Treat       Date:  2009-06

4.  Evaluation of multiple breathing states using a multiple instance geometry approximation (MIGA) in inverse-planned optimization for locoregional breast treatment.

Authors:  Alexander Lin; Jean M Moran; Robin B Marsh; James M Balter; Benedick A Fraass; Daniel L McShan; Marc L Kessler; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

5.  Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study.

Authors:  I Fragkandrea; V Kouloulias; P Mavridis; A Zettos; S Betsou; P Georgolopoulou; A Sotiropoulou; A Gouliamos; I Kouvaris
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

6.  Image-guided volumetric modulated arc therapy for breast cancer: a feasibility study and plan comparison with three-dimensional conformal and intensity-modulated radiotherapy.

Authors:  H Badakhshi; D Kaul; J Nadobny; B Wille; J Sehouli; V Budach
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

7.  A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT.

Authors:  W C Wu; C L Chan; Y W Wong; J P Cuijpers
Journal:  Br J Radiol       Date:  2009-09-01       Impact factor: 3.039

8.  Dosimetric Comparison of Three-Dimensional Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy Techniques (IMRT) with Radiotherapy Dose Simulations for Left-Sided Mastectomy Patients.

Authors:  Serhat Aras; Türkan İkizceli; Meryem Aktan
Journal:  Eur J Breast Health       Date:  2019-04-01

9.  Developing Multivariable Normal Tissue Complication Probability Model to Predict the Incidence of Symptomatic Radiation Pneumonitis among Breast Cancer Patients.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Liyun Chang; Hui-Min Ting; Yu-Jie Huang
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  Meta-analysis of incidence of early lung toxicity in 3-dimensional conformal irradiation of breast carcinomas.

Authors:  Kumar Gokula; Arul Earnest; Lea Choung Wong
Journal:  Radiat Oncol       Date:  2013-11-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.